Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced the appointment of Steven Altschuler, MD, as the ...
89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days.
Check the time stamp on this data. Updated AI-Generated Signals for 89bio Inc. (ETNB) available here: ETNB. Type a few ...
(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...
Inc. (NASDAQ:ETNB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. Two equities research ...
AI can spot patterns in the data from blood tests that can give an early warning of disease.
Pegozafermin is under clinical development by 89Bio and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase III drugs for Liver Cirrhosis have a 44% phase transition success ...
Pegozafermin is under clinical development by 89Bio and currently in Phase III for Fibrosis. According to GlobalData, Phase III drugs for Fibrosis does not have sufficient historical data to build an ...
Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia. Video, 00:03:33Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia ...
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback